Key Highlights

  • Humana (NYSE:HUM) advanced approximately 12% after hours and about 14.95% premarket to USD 445 after CMS 2027 Star Ratings lifted its biggest Medicare Advantage contract to 4 stars from 3.5, though another summary shows 16.5%.
  • Alignment Healthcare (NASDAQ:ALHC) declined approximately 23% to 24% after its California contract, about 81% of membership, was cut to 3.5 stars from 4, a concentrated exposure that magnified the effect.
  • Haemonetics (NYSE:HAE) rocketed 17.46% to USD 119.47, reportedly on an updated non-exclusive US Supply agreement with CSL Plasma for NexSys PCS devices, with rollout expected by the end of 2027.
  • Health Care Select Sector SPDR Fund (NYSEARCA:XLV) holds US health care companies, and the sector declined approximately 1.9% on October 8 even as the FDA approved Roche's Tecentriq early for colon cancer.

Humana (NYSE:HUM): Higher Stars, Higher Hopes

The Centers for Medicare and Medicaid Services released its 2027 Star Ratings after the close on October 8, 2026. Plans rated 4 or higher qualify for quality Bonus payments that fund richer benefits, so a half-star can change Revenue for many members. Humana's largest contract moved to 4 stars from 3.5, which could restore bonus eligibility for a large share of its members. Humana (NYSE:HUM) rose about 12% after hours and 14.95% premarket to USD 445, while a separate summary reports 16.5%. The figures are unreconciled and untimestamped, so the open should be checked. Baird upgraded the stock to Outperform with a USD 596 target, which implies about 34% upside from the premarket quote, a straightforward calculation and an analyst view, not a forecast we endorse. Risks include medical costs, government payment rates and utilization, because a better rating does not remove cost pressure. Ratings can also be appealed, and bonus payments arrive with a lag.

Alignment (NASDAQ:ALHC): One Contract, Most of the Business

Alignment Healthcare (NASDAQ:ALHC) moved the other way. Its California contract, which covers about 81% of its membership, fell to 3.5 stars from 4, below the level that qualifies for quality bonuses. Because so much of the Business sits in one contract, the rating hits a far larger share of revenue than it would at a diversified insurer. The stock declined approximately 23% to 24% in after-hours and premarket trading. The result is a reminder that concentration cuts both ways: when a rating rises, the benefit is large, and when it falls, so is the damage. Alignment (NASDAQ:ALHC) can appeal the rating and work to improve quality scores, but bonus changes affect the next plan year and do not reverse quickly. Investors should watch for company statements about the impact, appeals, enrollment trends in the fall open enrollment period and any change in guidance. Premarket quotes may differ from the regular open. The comparison with Humana (NYSE:HUM) also shows that Star Ratings are relative to plan quality and not a measure of company size, and that a small insurer can be hit hard by one contract. Peers with California exposure may also see a reaction as investors review their own ratings.

Haemonetics (NYSE:HAE): A Plasma Rollout Rally

Haemonetics (NYSE:HAE) ended the session at USD 119.47, up 17.46%, the top large-cap healthcare gainer of the day, which implies a prior close near USD 101.71, a straightforward calculation on the published figures. A recap attributed the move to an updated non-exclusive US supply agreement with CSL Plasma covering NexSys PCS plasma collection devices, with rollout expected by the end of 2027. Non-exclusive means CSL Plasma may buy elsewhere, and an earlier filing described no minimum purchase commitments, so Volume is not guaranteed. The company sells devices and disposable kits, a razor-and-blade model in which each installed device creates repeat revenue. The explanation comes from one recap and should be confirmed in the release and the 8-K. Haemonetics (NYSE:HAE) must convert rollout into reported sales, and a sharp one-day gain can reverse if installations lag. investors may wish to monitor for company commentary on pricing, volume and timing, and the upcoming quarterly results. Plasma collection depends on donor volumes and on the buying decisions of a few large networks, so customer concentration is a real risk. Competing device makers can also bid for the same networks. A rally of this size sets a high bar, because the share price now assumes that rollout will convert into sales on schedule and at acceptable margins. Readers should compare the post-move valuation with its historical range.

XLV (NYSEARCA:XLV): The Sector Backdrop and a Landmark Approval

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) holds hundreds of US health care names, and the sector declined approximately 1.9% on October 8, in sector prints that differ by source. That makes the three stock moves above even more notable. The FDA also approved Roche's Tecentriq for stage III colon cancer with deficient mismatch repair, ahead of its October 9 PDUFA date. The ATOMIC trial showed a 50% cut in the risk of recurrence or death, with 86% of patients free of disease at 36 months versus 76%. Roche trades over the counter as RHHBY and is not a core US holding, so the approval has no direct effect on the fund. It is a sentiment point about innovation. XLV investors should note that fund results depend on many companies at once, and that insurers, device makers and drug companies respond to different forces, including rates, regulation and reimbursement. Rising Treasury yields have also weighed on the sector. The Tecentriq approval applies only to a subset of patients with this type of tumor, so its commercial scale is limited, but it may encourage further research into immunotherapy after surgery. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers diversified exposure without relying on any one of these stories, although it cannot avoid a sector-wide decline.

Where Things Stand

October 8 showed how much health care results depend on single decisions: a ratings announcement, a supply agreement and a drug approval each moved individual names, while the sector fell. Humana (NYSE:HUM) gained from a higher rating. Alignment Healthcare (NASDAQ:ALHC) lost on a lower one. Haemonetics (NYSE:HAE) rallied on a plasma rollout, though the cause needs confirmation and the agreement is non-exclusive. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) reflects all of this plus rates. Recheck premarket moves at the open, since they are untimestamped snapshots. The next catalysts are company commentary on the ratings, the Haemonetics release and 8-K, and sector drivers such as Treasury yields, which touched about 5.35% on the 10-year intraday on October 8. Nothing here guarantees a continued move in any of the four.